Amporin Pharmaceuticals AG

Amporin Pharmaceuticals AG is an emerging Swiss biotech startup based in Basel and founded in 2024 by a small team of ex-Pharma neuroscientists and drug discovery and development experts. We are developing a breakthrough new class of small molecule amyloid pore inhibitors that can uniquely protect and repair cell membranes from the damage caused by toxic soluble misfolded protein oligomers, as the first potential acute oral disease-modifying treatments to stop and reverse the progression of over 50 deadly degenerative diseases. Together, these diseases affect over half a billion people and kill 3.6 million people each year at a total cost of USD 3 trillion per year. Our vision is to cure 6 major degenerative diseases with a simple pill, starting with Parkinson's disease and ALS.